IL108235A - Transdermal therapeutic system containing galanthamine - Google Patents

Transdermal therapeutic system containing galanthamine

Info

Publication number
IL108235A
IL108235A IL10823593A IL10823593A IL108235A IL 108235 A IL108235 A IL 108235A IL 10823593 A IL10823593 A IL 10823593A IL 10823593 A IL10823593 A IL 10823593A IL 108235 A IL108235 A IL 108235A
Authority
IL
Israel
Prior art keywords
galanthamine
tts according
esters
tts
transdermal therapeutic
Prior art date
Application number
IL10823593A
Other languages
English (en)
Other versions
IL108235A0 (en
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of IL108235A0 publication Critical patent/IL108235A0/xx
Publication of IL108235A publication Critical patent/IL108235A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL10823593A 1993-01-23 1993-12-30 Transdermal therapeutic system containing galanthamine IL108235A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4301783A DE4301783C1 (de) 1993-01-23 1993-01-23 Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil

Publications (2)

Publication Number Publication Date
IL108235A0 IL108235A0 (en) 1994-04-12
IL108235A true IL108235A (en) 1996-10-31

Family

ID=6478781

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10823593A IL108235A (en) 1993-01-23 1993-12-30 Transdermal therapeutic system containing galanthamine

Country Status (26)

Country Link
US (1) US5700480A (pl)
EP (1) EP0680325B1 (pl)
JP (1) JPH08505632A (pl)
KR (1) KR100300477B1 (pl)
AT (1) ATE216240T1 (pl)
AU (1) AU679032B2 (pl)
CA (1) CA2153572C (pl)
CZ (1) CZ287053B6 (pl)
DE (2) DE4301783C1 (pl)
DK (1) DK0680325T3 (pl)
ES (1) ES2176234T3 (pl)
FI (1) FI113744B (pl)
HR (1) HRP940028B1 (pl)
HU (1) HU221165B1 (pl)
IL (1) IL108235A (pl)
MY (1) MY109926A (pl)
NO (1) NO307497B1 (pl)
NZ (1) NZ259857A (pl)
PH (1) PH31473A (pl)
PL (1) PL175083B1 (pl)
PT (1) PT680325E (pl)
SI (1) SI9400024A (pl)
SK (1) SK281339B6 (pl)
WO (1) WO1994016707A1 (pl)
YU (1) YU48607B (pl)
ZA (1) ZA94414B (pl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4429791C2 (de) * 1994-08-23 1997-04-24 Lohmann Therapie Syst Lts Medizinischer Haftkleber auf Basis von Polyacrylaten und dessen Verwendung
DE19509663A1 (de) 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
AU732803B2 (en) * 1996-01-17 2001-05-03 National Starch And Chemical Investment Holding Corporation Adhesives resistant to skin-penetration enhancers
AT402691B (de) * 1996-01-26 1997-07-25 Sanochemia Ltd Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
DE69735656T2 (de) * 1996-07-15 2006-08-24 Alza Corp., Mountain View Vorrichtung zur transdermalen Verabreichung von Fluoxetin
DE19649534B4 (de) * 1996-11-29 2004-05-06 Lts Lohmann Therapie-Systeme Ag Verpackung aus Verbundpackstoff zum Verpacken von wirkstoffhaltigen Pflastern
DE19653605C2 (de) * 1996-12-20 2002-11-28 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme und dessen Verwendung zur Herstellung eines transdermalen Therapiesystems
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US6193993B1 (en) * 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
AU775914B2 (en) * 1998-12-24 2004-08-19 Janssen Pharmaceutica N.V. Controlled release galantamine composition
US6241998B1 (en) 1999-02-02 2001-06-05 Acutek International Dermatological patch
DE19906977C1 (de) * 1999-02-19 2000-06-15 Lohmann Therapie Syst Lts Desoxypeganin-TTS und seine Verwendung
WO2001026648A1 (en) * 1999-10-13 2001-04-19 Senju Pharmaceutical Co., Ltd. Ophthalmic adhesive preparations for percutaneous absorption
JP2003516947A (ja) 1999-12-10 2003-05-20 デイビス、ボニー ニコチン様物質受容体のモジュレーターとしてのガランタミンおよびリコラミンの類似物
US7445929B2 (en) * 2000-05-26 2008-11-04 Dainippon Sumitomo Pharma Co., Ltd. Recombinant adenovirus vector having a reduced side effect
FR2814368B1 (fr) * 2000-09-26 2004-05-07 Pf Medicament Preparation pharmaceutique a base d'oxans
DE10141652B4 (de) * 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
CA2551946A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galantamine
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
WO2006124584A2 (en) * 2005-05-13 2006-11-23 Alza Corporation Multilayer drug delivery system with barrier against reservoir material flow
WO2007035941A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal galantamine delivery system
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
DE102008059054A1 (de) 2008-11-26 2010-05-27 Otto Bock Pur Life Science Gmbh Polyurethanpflaster für die transdermale Applikation von Wirkstoffen und Verfahren zu dessen Herstellung
CA2815898C (en) 2010-11-17 2018-12-18 Hexal Ag Transdermal therapeutic system comprising buprenorphine
KR101317158B1 (ko) 2011-02-18 2013-10-15 조선대학교산학협력단 갈란타민 또는 그의 염을 함유하는 경피흡수제제
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP6285820B2 (ja) * 2014-08-07 2018-02-28 久光製薬株式会社 ガランタミン含有経皮吸収製剤
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US20180008612A1 (en) * 2016-07-11 2018-01-11 Taho Pharmaceuticals Ltd. Transdermal delivery system containing galantamine or salts thereof
MX2022005168A (es) 2019-11-06 2022-06-08 Smartech Topical Inc Formulaciones topicas de inhibidores de la ciclooxigenasa y su uso.
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1239318A (en) * 1983-04-27 1988-07-19 Hans R. Hoffmann Pharmaceutical product preferably in medical bandage form and process for producing them
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE3843239C1 (pl) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
EP0584185B1 (en) * 1991-05-14 1999-08-11 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors

Also Published As

Publication number Publication date
YU48607B (sh) 1998-12-23
HUT72643A (en) 1996-05-28
NO307497B1 (no) 2000-04-17
AU679032B2 (en) 1997-06-19
YU2694A (sh) 1996-10-18
CZ287053B6 (en) 2000-08-16
HRP940028A2 (en) 1996-06-30
AU5881794A (en) 1994-08-15
SI9400024A (en) 1994-09-30
ATE216240T1 (de) 2002-05-15
FI953533L (fi) 1995-07-21
CA2153572A1 (en) 1994-08-04
PL309603A1 (en) 1995-10-30
NO952907L (no) 1995-07-21
HU9501928D0 (en) 1995-09-28
WO1994016707A1 (de) 1994-08-04
PL175083B1 (pl) 1998-10-30
SK281339B6 (sk) 2001-02-12
HRP940028B1 (en) 2000-02-29
KR960700060A (ko) 1996-01-19
CA2153572C (en) 2006-01-03
NZ259857A (en) 1996-03-26
FI953533A0 (fi) 1995-07-21
DK0680325T3 (da) 2002-08-05
HU221165B1 (en) 2002-08-28
IL108235A0 (en) 1994-04-12
NO952907D0 (no) 1995-07-21
ZA94414B (en) 1994-08-31
PT680325E (pt) 2002-09-30
MY109926A (en) 1997-09-30
JPH08505632A (ja) 1996-06-18
EP0680325B1 (de) 2002-04-17
CZ184295A3 (en) 1996-01-17
KR100300477B1 (ko) 2001-10-22
DE4301783C1 (de) 1994-02-03
FI113744B (fi) 2004-06-15
PH31473A (en) 1998-11-03
SK88995A3 (en) 1996-05-08
EP0680325A1 (de) 1995-11-08
DE59410103D1 (de) 2002-05-23
ES2176234T3 (es) 2002-12-01
US5700480A (en) 1997-12-23

Similar Documents

Publication Publication Date Title
US5700480A (en) Transdermal therapeutic system comprising galanthamine as active component
US6791003B1 (en) Dual adhesive transdermal drug delivery system
US5240711A (en) Transdermal therapeutic system comprising as active component buprenorphine
KR950015061B1 (ko) 활성 성분으로서 부프레노르핀을 포함하는 경피 치료 시스템
US9295655B2 (en) Fentanyl transdermal patch
WO2007099966A1 (ja) 経皮吸収型製剤
US6558696B1 (en) Desoxypeganine
FI118885B (fi) Skopolamiinilaastari
AU694115B2 (en) Systems for controlled release of pilocarpine
WO2002003970A2 (de) Matrixkontrolliertes transdermales system für stabile derivate der ace-hemmer
RU2432179C2 (ru) Фармацевтический препарат абсорбционного типа для чрезкожного введения
CA2006425C (en) Transdermal therapeutical system comprising norpseudoephedrine as active component
US5705186A (en) Pharmaceutical composition for the systemic transdermal administration having the active substance morphine-6-glucuronide
US6805878B2 (en) Transdermal administration of ACE inhibitors
KR20010074687A (ko) 글리세롤트리니트레이트 함유 조성물, 상기 조성물의제조방법 및 용도

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired